GlaxoSmithKline – Q1 update, still further share price upside as demerger nears
By Tom Winnifrith and Steve Moore | Monday 2 May 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.